Pharmacogenetic Studies of Paclitaxel in the Treatment of Ovarian Cancer

Basic and Clinical Pharmacology and Toxicology - Tập 104 Số 2 - Trang 130-137 - 2009
Henrik Gréen1, Peter Söderkvist2, Per Rosenberg3, Rajaa A. Mirghani4,5, Per Rymark6, Elisabeth Åvall Lundqvist7, Curt Peterson1
1Division of Drug Research, Faculty of Health Sciences, Linköping University, Linköping,
2Division of Cell Biology, Department of Clinical and Experimental Medicine, Faculty of Health Sciences, Linköping University, Linköping,
3Department of Oncology, Linköping University Hospital, Linköping
4Division of Clinical Pharmacology, Department of Laboratory Medicine, Karolinska University Hospital, Huddinge, Karolinska Institutet, Stockholm,
5Present affiliation: Department of Clinical Toxicology, Central Laboratories & Blood Bank, King Fahad Medical City, Riyadh 11525, Kingdom of Saudi Arabia.
6Department of Obstetrics and Gynaecology, Central Hospital, Västerås, and
7Department of Gynaecologic Oncology, Radiumhemmet, Karolinska University Hospital, Solna, Stockholm, Sweden

Tóm tắt

Abstract:  The purpose of this study was to evaluate the role of sequence variants in the CYP2C8, ABCB1 and CYP3A4 genes and the CYP3A4 phenotype for the pharmacokinetics and toxicity of paclitaxel in ovarian cancer patients. Thirty‐eight patients were treated with paclitaxel and carboplatin. The genotypes of CYP2C8*1B, *1C, *2, *3, *4, *5, *6, *7, *8 and P404A, ABCB1 G2677T/A and C3435T, as well as CYP3A4*1B, were determined by pyrosequencing. Phenotyping of CYP3A4 was performed in vivo with quinine as a probe. The patients were monitored for toxicity and 23 patients underwent a more extensive neurotoxicity evaluation. Patients heterozygous for G/A in position 2677 in ABCB1 had a significantly higher clearance of paclitaxel than most other ABCB1 variants. A lower clearance of paclitaxel was found for patients heterozygous for CYP2C8*3 when stratified according to the ABCB1 G2677T/A genotype. In addition, the CYP3A4 enzyme activity in vivo affected which metabolic pathway was dominant in each patient, but not the total clearance of paclitaxel. The exposure to paclitaxel correlated to the degree of neurotoxicity. Our findings suggest that interindividual variability in paclitaxel pharmacokinetics might be predicted by ABCB1 and CYP2C8 genotypes and provide useful information for individualized chemotherapy.

Từ khóa


Tài liệu tham khảo

10.2217/17410541.3.1.33

Walle T, 1995, Taxol metabolism and disposition in cancer patients, Drug Metab Dispos, 23, 506

Harris JW, 1994, Metabolism of taxol by human hepatic microsomes and liver slices: participation of cytochrome P450 3A4 and an unknown P450 enzyme, Cancer Res, 54, 4026

Rahman A, 1994, Selective biotransformation of taxol to 6α‐hydroxytaxol by human cytochrome P450 2C8, Cancer Res, 54, 5543

Sonnichsen DS, 1995, Variability in human cytochrome P450 paclitaxel metabolism, J Pharmacol Exp Ther, 275, 566

10.1007/BF00689197

10.1021/jm00031a022

10.1016/S0006-2952(02)01354-0

10.1097/00008571-200110000-00006

10.1124/dmd.105.003830

10.1248/bpb.24.1427

10.2133/dmpk.17.374

10.1016/S0169-409X(02)00066-2

10.1016/j.bbrc.2005.09.020

10.1177/009127009703700121

10.1007/s00228-003-0575-5

10.1006/gyno.2002.6738

10.1016/j.ygyno.2003.11.053

10.1073/pnas.94.5.2031

10.1200/JCO.1995.13.8.2039

10.1073/pnas.97.7.3473

Tanabe M, 2001, Expression of P‐glycoprotein in human placenta: relation to genetic polymorphism of the multidrug resistance (MDR)‐1 gene, J Pharmacol Exp Ther, 297, 1137

10.1067/mcp.2001.117412

10.1158/1078-0432.CCR-05-0950

10.1200/JCO.2006.10.4752

10.1016/S0009-9236(99)70008-1

10.1016/S0378-4347(00)00577-6

10.1002/rcm.2567

10.1007/s002800050723

10.1016/j.clpt.2003.09.012

10.1517/14622416.5.7.895

10.1254/jphs.FP0040603

10.1124/mol.62.1.1

10.1016/S0006-2952(03)00178-3

10.1097/00008571-200308000-00006

10.1097/01.fpc.0000230113.03710.34

10.1111/j.1525-1438.2006.00593.x

10.1177/0091270005276204

10.1016/j.ejca.2006.06.017

10.1038/sj.tpj.6500434

10.1158/1078-0432.CCR-05-1152

10.1016/S0009-9236(03)00228-5

10.1016/j.clpt.2004.04.006

10.1158/1078-0432.CCR-05-0298

10.1200/JCO.1997.15.1.317

Mielke S, 2005, Paclitaxel pharmacokinetics and response to chemotherapy in patients with advanced cancer treated with a weekly regimen, Anticancer Res, 25, 4423

10.1200/JCO.1993.11.11.2127

10.1200/JCO.1995.13.1.180

Thông tin
Thông tin xuất bản

Basic and Clinical Pharmacology and Toxicology

Tập 104 Số 2

130-137

Thông tin tác giả